ABT-107 is a high-affinity and selective α7nAChR agonist that reduces PD motor deficits and nigrostriatal damage by enhancing striatal dopaminergic function in 6-hydroxydopamine-induced PD rat models [66]. Here, CHRNA7 is linked to Parkinson disease.